Explore strategies for controlling COPD and improving health, with a focus on management and lifestyle changes.

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Injurious falls are common among people with chronic obstructive pulmonary disease (COPD) in the two years before de ...

Centre, a national research platform led by Nanyang Technological University, Singapore’s (NTU Singapore) Lee Kong Chian School of Medicine (LKCMedicine), will lead a multi-institutional research ...

A recent study conducted by researchers from Seattle-based University of Washington and Durham, N.C.-based Duke University found a strong association between the use of fall-risk increasing drugs and ...

Certain Medicare plans typically cover at least part of the cost of inhalers for COPD. There are also several ways to further save on costs.

Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

Among patients with COPD who experienced an exacerbation, the risk for cardiovascular events was highest in the following 2 weeks and stayed elevated more than 1 year after, according to study results ...

FAPI PET—can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing physicians with an early marker for disease progression. This approach has ...

Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further ...

Chronic lower respiratory diseases, including chronic obstructive pulmonary disease (COPD), are the sixth leading cause of death in the United States, according to the U.S. Centers for Disease Control ...